---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-044598"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2023-12-12T23:59:59+00:00"
generated_at: "2026-06-07T14:23:15.200135+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Calidi Biotherapeutics enters $25M equity line with Yorkville; director resignation and replacement

## Summary
- SEPA provides up to $25M (expandable to $50M) of common stock at 97% of market price over 36 months.
- Commitment fee of $250,000 in shares and $25,000 structuring fee; advance capped at 5M shares or 100% of 5-day avg volume.
- Director Thomas Vecchiolla resigns effective Jan 1, 2024; David LaPre appointed to fill vacancy as independent director.
- Issuance capped at 19.99% of outstanding shares unless shareholder approval or price test met; requires effective registration statement.

## SEC filing metadata
- accession: 0001493152-23-044598
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2023-12-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000149315223044598/0001493152-23-044598-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000149315223044598/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-044598
- JSON: https://secwatch.observer/filing/0001493152-23-044598.json
- Plain text: https://secwatch.observer/filing/0001493152-23-044598.txt

## Key facts
- Executive change
  David LaPre was appointed as Director at Calidi Biotherapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: the Board appointed Mr. David LaPre as a director to fill the vacancy in connection with Mr. Vecchiolla’s departure, effective January 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000149315223044598/0001493152-23-044598-index.htm
- Executive change
  Thomas Vecchiolla resigned as Director at Calidi Biotherapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: Mr. Thomas Vecchiolla announced that he will be resigning as a director of the Board of Directors (the “Board”) of Calidi Biotherapeutics, Inc. (the “Company”) effective January 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000149315223044598/0001493152-23-044598-index.htm
- Material Agreements
  Calidi Biotherapeutics, Inc. entered into Standby Equity Purchase Agreement with YA II PN, Ltd. valued at up to $25,000,000 (effective 2023-12-10).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: YA II PN, Ltd.
  - Value: up to $25,000,000
  - Effective: 2023-12-10
  source text: On December 10, 2023, Calidi Biotherapeutics, Inc. (the “Company”) entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, Ltd., a Cayman Island exempt limited partnership (“Yorkville”). Pursuant to the SEPA, the Company will have the right, but not the obligation, to sell to Yorkville up to $25,000,000 of its shares of Common Stock, par value $0.0001 per share (the “Common Stock”), at the Company’s request any time during the 36 months following the execution of the SEPA.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000149315223044598/0001493152-23-044598-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.